Low-level aviremic hepatitis C virus (HCV) RNA replication in the immune blood PBMCs/WBCs (secondary occult HCV infectioi as one of the primary interferon-free DAA therapy outcomes in real clinical practice in antiviral therapy-naive patients with chronic HCV RNA viremia (a description of a series of cases)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper presents the results of the authors’ own pilot study of the prevalence of secondary occult hepatitis C virus (HCV) infection after various primary interferon-free (direct-acting antivirals (DAA)) therapy regimens with original inhibitor drugs in real clinical practice. Examinations have been made in 27 patients randomly selected from 261 ones who achieved a traditional plasma sustained virological response at 12 weeks after the end of a DAA therapy cycle confirmed by HCV RNA aviremia.

Full Text

Restricted Access

About the authors

A. Yakovlev

Saint Petersburg State University; S.P. Botkin Clinical Infectious Diseases Hospital

D. Sulima

Acad. I.P. Pavlov First Saint Petersburg State Medical University

V. Larionov

V.A. Almazov Medical Research Center

V. Koryagin

OOO «Exclusive» Medical Consulting Dental Center

M. Sharipova

OOO «Exclusive» Medical Consulting Dental Center

I. Fedunyak

S.P. Botkin Clinical Infectious Diseases Hospital; I.I. Mechnikov North-Western State Medical University

V. Musatov

Saint Petersburg State University; S.P. Botkin Clinical Infectious Diseases Hospital

G. Kachenya

S.P. Botkin Clinical Infectious Diseases Hospital

E. Doguzhneva

S.P. Botkin Clinical Infectious Diseases Hospital

O. Sokolova

Saint Petersburg State University; S.P. Botkin Clinical Infectious Diseases Hospital

O. Gorchakova

Acad. I.P. Pavlov First Saint Petersburg State Medical University

A. Semenov

I.I. Mechnikov North-Western State Medical University; Research Institute of Epidemiology and Microbiology

E. Zueva

Research Institute of Epidemiology and Microbiology

Yu. Ostankova

Research Institute of Epidemiology and Microbiology

S. Prosvernitsyn

OOO «Exclusive» Medical Consulting Dental Center; I.I. Mechnikov North-Western State Medical University

S. Kiyashko

OOO «Exclusive» Medical Consulting Dental Center; V.A. Almazov Medical Research Center

Yu. Chornoguz

Research Institute of Epidemiology and Microbiology

D. Valutite

Research Institute of Epidemiology and Microbiology

References

  1. Ferri C., Ramos-Casals M., Zignego A.L. et al. International diagnostic guidelinesforpatients with HCV- expertstatement // Autoimmun. Rev. - 2016; 15 (12): 1145-60. doi: 10.1016/j.autrev.2016.09.006
  2. McHutchinson J., Davis G., Esteban-Mur R. et al. Durability of sustainedviralresponse in patients with chronic hepatitis C. aftertreatment with interferon alpha-2b aloneor in combination with ribavirin // Hepatology. - 2001; 34: 244.
  3. Shiratori Y., Imazeki F., Moriyama M. et al. Histologicimprovement of fibrosis in patients with hepatitis C. whohavesustainedresponse to interferon therapy // Ann. Intern. Med. - 2000; 132: 517-24.
  4. Castillo I., Pardo M., Bartolome J. et al. Occult Hepatitis C. Virus Infection in Patients in Whom the Etiology of PersistentlyAbnormal Results of Liver-Function Tests Is Unknown // J. Infect. Dis. - 2004; 189 (1): 7-14.
  5. Attar В., VanThiel D. Review Article. A New Twist to a Chronic HCV Infection: Occult Hepatitis C. // Gastroenterol. Res. Pract. - 2015; 2015: 579147. http://dx.doi. org/10.1155/2015/579147
  6. AbdAlla M., ElAwady M. Hepatitis C. virus RNA strands detection in peripheral blood mononuclear cells legitimizes virus eradication in negative serumpcrnaive and post-treatment patients // J. Clin. Transl. Hepatol. - 2017; 5 (1): 1-8. doi: 10.14218/JCTH.2016.00054
  7. Innes H., McDonald S., Hayes P. et al. Mortality in hepatitis C. patients who achieve a sustained viral response compared to the general population // J. Hepatol. - 2017; 66 (1): 19-27. https://doi.org/10.1016/jjhep.2016.08.004
  8. Yousif M., ElsadekFakhr A. et al. Prevalence of occult hepatitis C. virus infection in patients who achieved sustained virologic response todirect-acting antiviral agents // Infez. Med. - 2018; 26 (3): 237-43.
  9. Mekky M., Sayed H., Abdelmalek M. et al. Prevalence and predictors of occult hepatitis C. virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi centerstudy // Infect. Drug Resist. - 2019; 12: 273-9. DOI: 10.2147 / IDR.S181638
  10. Wroblewska A., Lorenc B., Cheba M. et al. Neutrocyte to lymphocyte ratiopredicts the presence of a replicative hepatitis C. virus strand after therapy with direct acting antivirals // Clin. Exp. Med. - 2019; 19: 401-6. https://doi.org/10.1007/ s10238-019-00561-y
  11. Lybecka C., Brenndorferc E., Sallbergc M. et al. Long-term follow-up aftercure from chronic hepatitis C. virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients // Eur. J. Gastroenterol. Hepatol. - 2019; 31 (4): 506-13. doi: 10.1097/MEG.0000000000001316
  12. Знойко О.О., Линькова Ю.Н., Морозова М.А. и др. Клинический опыт применения схемы тройной терапии, включающей цепэгинтерферон альфа-2b, симепревир и рибавирин, у пациентов с хроническим гепатитом С. генотипа 1 // Инфекционные болезни: новости, мнения, обучение. - 2016; 2 (15): 100-9
  13. Сулима Д.Л., Лиознов Д.А., Яковлев А.А. и др. Первый в России опыт применения GLE/PIB для лечения HCV-инфекции генотипа 3а с криоглобулинемией и сопутствующей HBV-инфекцией у пациента с ХБП С5д, леченного гемодиализом и ожидавшего трансплантацию почки // Врач. - 2019; 30 (2): 3-13 https://doi.org/10.29296/25877305-2019-02-01
  14. Сулима Д.Л., Соколова О.И., Ларионов В.А. и др. Безинтерфероновая DAA-терапия у пациентов с хронической HCV-инфекцией (новая гипотеза на основании 3-летнего проспективного наблюдательного исследования двух клиник Санкт-Петербурга) // Современная медицина. - 2019; 3 (15): 7-29
  15. Chomczynski P., Sacchi N. // Single-stepmethod of RNA isolation by acid guanidinium thiocyanate-phenol-chloroformextraction // Anal. Biochem. - 1987; 162 (1): 156-9.
  16. EASL Recommendations on Treatment of Hepatitis C. 2015 // J. Hepatol. -2015; 63: 199-236. doi: 10.1016/j.jhep.2015.03.025
  17. EASL Recommendations on Treatment of Hepatitis C. 2016 // J. Hepatol. -2017; 66: 153-94. https://doi.org/10.1016/jjhep.2016.09.001
  18. EASL Recommendations on Treatment of Hepatitis C. 2018 // J. Hepatol. -2018; 69: 461-511. https://doi.org/10.1016/jjhep.2018.03.026
  19. Приходько Е.М., Селиверстов П.В., Адылов Ш.Ф. и др. Возможности регенеративной терапии в лечении пациентов с хроническим гепатитом // Гастроэнтерология Санкт-Петербурга. - 2018; 2: 91-2

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies